# Dose-finding, Safety and Efficacy Study of Radium-223 Dichloride (XOFIGO) in RCC Patients With Bone Metastases. (EIFFEL)

> **NCT02880943** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie** · enrollment: 42 (estimated)

## Conditions studied

- Clear-cell Metastatic Renal Cell Carcinoma
- Bone Metastases

## Interventions

- **DRUG:** XOFIGO

## Key facts

- **NCT ID:** NCT02880943
- **Lead sponsor:** Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-10
- **Primary completion:** 2020-10
- **Final completion:** 2021-02
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2016-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02880943

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02880943, "Dose-finding, Safety and Efficacy Study of Radium-223 Dichloride (XOFIGO) in RCC Patients With Bone Metastases. (EIFFEL)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02880943. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*